{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095481","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.504660+00:00","generated_at":"2026-05-31T10:05:43.755188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025","bullets":["Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.","Cash, equivalents, and short-term investments $179.3M as of June 30, 2024.","BBI-355 combo cohort enrollment slower than expected; initial proof-of-concept data now H2 2025.","BBI-825 first patient dosed in April 2024; initial data also expected H2 2025.","Workforce reduced and operations streamlined to extend runway into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095481","json":"https://secwatch.observer/filing/0000950170-24-095481.json","markdown":"https://secwatch.observer/filing/0000950170-24-095481.md","text":"https://secwatch.observer/filing/0000950170-24-095481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/0000950170-24-095481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/bold-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:43.755188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}